Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638011 · ClinicalTrials.gov registry record · Phase 4
A Comparison of the Post-C/S Analgesic Effects of Neuraxial Duramorph vs Bilateral TAP Block With Liposomal Bupivacaine
A Phase 4 study, sponsored by Maimonides Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
NCT03638011 is a Phase 4 study that was terminated before completion, run by Maimonides Medical Center. The registered enrollment target is 71 participants.
The verdict
NCT03638011, a Phase 4 study, was terminated before completion, sponsored by Maimonides Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
Study Summary
The primary objective is to reduce or eliminate the use of all narcotics/opiates for post Cesarean section pain management. The investigators hypothesize that in comparison with epidural or intrathecal Duramorph, a TAP block with liposomal bupivacaine (Exparel) will provide better, longer-acting pain control and will significantly reduce the use of post-operative IV or p.o. opiates. This is a prospective, randomized clinical trial.
Interventions
- DRUG Exparel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03638011
The ClinicalTrials.gov registry entry for NCT03638011 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exparel is the first listed.
NCT03638011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03638011 about?
NCT03638011 is a clinical study titled "A Comparison of the Post-C/S Analgesic Effects of Neuraxial Duramorph vs Bilateral TAP Block With Liposomal Bupivacaine". The primary objective is to reduce or eliminate the use of all narcotics/opiates for post Cesarean section pain management. The investigators hypothesize that in comparison with epidural or intrathecal Duramorph, a TAP block with liposomal bupivacaine (Exparel) will provide better, longer-acting pai...
What is the current status of trial NCT03638011?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2018-09-25. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03638011?
The interventions under investigation include: Exparel (DRUG).
Who is sponsoring clinical trial NCT03638011?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.